Education
About Us
Working with TipRanks
Follow Us
Apollomics (APLM)
NASDAQ:APLM
APLM Stock Chart & Stats
$36.65
-$0.28(-2.62%)
At close: 4:00 PM EST
$36.65
-$0.28(-2.62%)
Day’s Range― - ―
52-Week Range$3.66 - $42.12
Previous CloseN/A
Volume6.18K
Average Volume (3M)72.65K
Market Cap
$40.44M
Enterprise Value$1.95M
Total Cash (Recent Filing)$9.77M
Total Debt (Recent Filing)$966.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Sep 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.91
Shares Outstanding1,103,348
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.86
Price to Sales (P/S)45.62
P/FCF Ratio-0.31
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue9.86
Enterprise Value/Gross Profit9.86
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $3.66 and its highest was $42.12 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $40.44M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Sep 25, 2025 which is 26 days ago.
How were Apollomics’s earnings last quarter?
Apollomics released its earnings results on Apr 03, 2025. The company reported -$16.913 earnings per share for the quarter, missing the consensus estimate of N/A by -$16.913.
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 1,103,348 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Apollomics reported an EPS of -$16.913 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
Apollomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
197.48%
12-Months-Change
Fundamentals
Return on Equity
-233.67%
Trailing 12-Months
Asset Growth
-76.35%
Trailing 12-Months
Company Description
Apollomics
Apollomics (APLM) is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and other serious diseases. The company specializes in the research and development of novel drug candidates that target specific pathways involved in tumor growth and progression. Apollomics operates primarily in the biotechnology sector, with a portfolio that includes various therapeutic agents currently undergoing clinical trials aimed at addressing unmet medical needs in oncology.
Technical Analysis
Soligenix
―
MetaVia
―
TransCode Therapeutics
―
Silexion Therapeutics
―
Lipella Pharmaceuticals, Inc.
―
Ownership Overview
―
Insiders
0.04% Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---